Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2020-06-21 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
关于收到上海证券交易所《关于对天士力医药集团股份有限公司重大资产出售草案信息披露的问询函》的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company regarding a regulatory inquiry letter received from the Shanghai Stock Exchange about a major asset sale draft. It contains detailed questions and requests for further disclosure related to the asset sale, valuation methods, guarantees, legal disputes, and other transaction details. The document is a formal regulatory announcement responding to a regulatory body inquiry and does not contain financial statements or a full report itself. It is relatively short (3736 characters) and serves as a disclosure announcement rather than the actual asset sale report or financial report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and compliance documents that do not fit other specific categories.
2020-06-21 Chinese
2020年第一次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled "2020 年第一次临时股东大会会议资料" which translates to "2020 First Extraordinary General Meeting (EGM) Materials." It contains detailed agenda items, voting procedures, and multiple proposals related to the company's business decisions, specifically about the spin-off and listing of a subsidiary on the Shanghai Stock Exchange's STAR Market (科创板). The content includes legal compliance, financial data summaries, and shareholder voting instructions. This is clearly a set of materials prepared for a shareholders' meeting, not the meeting minutes or voting results themselves. It is not an annual report, earnings release, or any other financial report. It is also not a proxy solicitation or voting results announcement. The document is a presentation or informational packet for shareholders to review before or during the meeting. Therefore, it fits the category of AGM Information (AGM-R), which includes presentations and materials shared during a general meeting (including extraordinary meetings). The document length and detail support this classification with high confidence.
2020-06-17 Chinese
重大资产出售报告书（草案）
Capital/Financing Update Classification · 95% confidence The document is titled as a "重大资产出售报告书 (Draft)" which translates to "Major Asset Sale Report (Draft)". It includes detailed sections such as transaction overview, pricing, compliance analysis, financial accounting information, risk factors, and opinions from independent directors and intermediaries. The content is comprehensive and relates to a significant asset disposal transaction by the company. This type of document is typical of a Capital/Financing Update or Major Asset Restructuring filing rather than a general annual report or earnings release. It is not a simple announcement or a brief summary but a full detailed report on a major asset sale transaction. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content confirm it is a full report, not just an announcement or certification.
2020-06-14 Chinese
国信证券股份有限公司关于公司重大资产出售之独立财务顾问报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" related to a "Major Asset Sale" by TianShiLi Pharmaceutical Group Co., Ltd. It is prepared by GuoXin Securities Co., Ltd. The content includes detailed analysis of the transaction, compliance with laws and regulations, financial data, valuation reports, risk disclosures, and opinions on the fairness and reasonableness of the transaction. The document is lengthy (15,000 characters) and contains substantive financial and legal analysis related to a significant corporate transaction. It is not a simple announcement or a brief summary but a comprehensive advisory report. This type of document fits the category of an Audit Report / Information (AR), as it is a standalone report providing audit-related opinions, valuation, and compliance analysis for a major asset sale, distinct from a full Annual Report or Earnings Release. It is not a regulatory filing or announcement, nor a management or board change notice. Therefore, the appropriate classification is AR with high confidence. FY 2019
2020-06-12 Chinese
国信证券股份有限公司关于公司重大资产出售摊薄即期回报及其填补措施的核查意见
Audit Report / Information Classification · 95% confidence The document is a formal opinion from Guosen Securities Co., Ltd. acting as an independent financial advisor regarding a major asset sale by Tasly Pharmaceutical Group Co., Ltd. It discusses the dilution of immediate returns due to the transaction and the measures taken to compensate for this dilution. The document references regulatory guidelines from Chinese authorities related to capital market investor protection and dilution of immediate returns in major asset restructurings. It includes detailed analysis of the impact on earnings per share, risk warnings, measures to improve company operations and investor returns, and commitments from company directors and controlling shareholders. The document is a standalone audit or advisory report focused on the financial and regulatory implications of a specific transaction, rather than a full annual or interim report, earnings release, or announcement. It does not contain comprehensive financial statements but provides an expert opinion on compliance and financial impact. Therefore, it fits the category of an Audit Report / Information (AR). The document length is 2598 characters, which is consistent with a detailed advisory opinion rather than a brief announcement or a full report. FY 2019
2020-06-12 Chinese
2019年度备考合并财务审阅报告
Audit Report / Information Classification · 95% confidence The document contains a detailed review report (审阅报告) and pro forma consolidated financial statements (备考合并财务报表) for the fiscal year ending December 31, 2019, including balance sheets, income statements, and extensive notes. It is issued by an accounting firm (天健) and addresses the shareholders of Tianjin Tasly Pharmaceutical Group Co., Ltd. The document includes financial data, accounting notes, and explanations related to a major asset restructuring. The presence of an auditor's review report and detailed financial statements indicates this is an Audit Report / Information document rather than a full Annual Report (10-K) or an Interim Report. The document is substantive and not a mere announcement or certification. Therefore, the appropriate classification is Audit Report / Information (AR).
2020-06-12 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.